StockData
Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc. (TELO) stock

TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.42−0.06 (-12.04%)

Close on Nov 17, 2026Market cap $29.10MP/E –Yield –

Telomir Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$2.19M–
Q1 FY2024Mar 31, 2024$1.92M–

More Telomir Pharmaceuticals figures

See a number that looks wrong?